Large expert-curated database for benchmarking document similarity detection in biomedical literature search

Document recommendation systems for locating relevant literature have mostly relied on methods developed a decade ago. This is largely due to the lack of a large offline gold-standard benchmark of relevant documents that cover a variety of research fields such that newly developed literature search techniques can be compared, improved and translated into practice. To overcome this bottleneck, we have established the RElevant LIterature SearcH consortium consisting of more than 1500 scientists from 84 countries, who have collectively annotated the relevance of over 180 000 PubMed-listed articles with regard to their respective seed (input) article/s. The majority of annotations were contributed by highly experienced, original authors of the seed articles. The collected data cover 76% of all unique PubMed Medical Subject Headings descriptors. No systematic biases were observed across different experience levels, research fields or time spent on annotations. More importantly, annotations of the same document pairs contributed by different scientists were highly concordant. We further show that the three representative baseline methods used to generate recommended articles for evaluation (Okapi Best Matching 25, Term Frequency-Inverse Document Frequency and PubMed Related Articles) had similar overall performances. Additionally, we found that these methods each tend to produce distinct collections of recommended articles, suggesting that a hybrid method may be required to completely capture all relevant articles. The established database server located at https://relishdb.ict.griffith.edu.au is freely available for the downloading of annotation data and the blind testing of new methods. We expect that this benchmark will be useful for stimulating the development of new powerful techniques for title and title/abstract-based search engines for relevant articles in biomedical research.Peer reviewe

Developmentally Appropriate Practice for Children

Developmentally appropriate practice is the basis for quality early learning and the focus of the 2009 revision of the NAEYC Position Statement but what does it mean for Catholic Schools? In the Marianist tradition to Learn, Lead and Serve , participants will LEARN how changes in the document reflect the demands of the 21st century, support development, and help young children start school ready to learn. Participants will be encouraged to LEAD as they explore how the revised position statement is being practiced in their Catholic school or parish setting and make a plan for improvement. Finally, participants will SERVE by submitting examples of high quality practice that may be selected to be part of the Bombeck Institute Showcase of Excellence

Authoring Interactive Fictional Stories in Object-Based Media (OBM)

This paper introduces a generic (i.e. production-independent) framework for OBM storytelling. Aiming to function as a complete end-to-end (from conception to realisation) reference for authoring OBM narrative content, it proposes an integrated model that includes the three essential levels: conceptual, technological and aesthetic. At the conceptual level, we introduce a set of abstractions which provide a unified reference for thinking, describing and analysing interactive narrative structures of OBM content. Their recursive nature make our model stand out in terms of its power of expression. These abstractions have direct one-to-one operational counterparts implemented in our production-independent authoring toolkit – Cutting Room. This ensures that any specific story design within the proposed conceptual model is directly realisable as an OBM production. This isomorphic relationship between the abstract concepts and their operationalisation is another distinguishing aspect of our overall proposition. We have validated the model at the aesthetic level through the production of the interactive film What is Love?, experienced by over 900 people at the media art festival Mediale 2018 in York, UK, and evaluated through a dedicated questionnaire by 94 of them. As the foundations of OBM storytelling have not yet been established, we trust this paper constitutes a significant milestone in its development

Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial

IMPORTANCE: Individuals with Down syndrome (DS) are at high risk of developing Alzheimer disease due to an increased dose of the amyloid precursor protein gene, APP, which leads to increased levels of full-length APP and its products, including amyloid-β (Aβ). The liposome-based antiamyloid ACI-24 vaccine is intended to treat neurological disorders caused by misfolded Aβ pathological protein. However, the safety, tolerability, and immunogenicity of the ACI-24 vaccine among adults with DS have not been fully examined. OBJECTIVE: To assess the safety and tolerability of the ACI-24 vaccine among adults with DS as well as its ability to induce immunogenicity measured by anti-Aβ immunoglobulin G titers. DESIGN, SETTING, AND PARTICIPANTS: This multicenter double-blind placebo-controlled dose-escalation phase 1b randomized clinical trial was conducted at 3 US academic medical centers with affiliated Down syndrome clinics between March 30, 2016, and June 29, 2020. A total of 20 adults with DS were screened; of those, 16 adults were eligible to participate. Eligibility criteria included men or women aged 25 to 45 years with cytogenetic diagnosis of either trisomy 21 or complete unbalanced translocation of chromosome 21. Between April 27, 2016, and July 2, 2018, participants were randomized 3:1 into 2 dose-level cohorts (8 participants per cohort, with 6 participants receiving the ACI-24 vaccine and 2 receiving placebo) in a 96-week study. Participants received 48 weeks of treatment followed by an additional 48 weeks of safety follow-up. INTERVENTIONS: Participants were randomized to receive 7 subcutaneous injections of ACI-24, 300 μg or 1000 μg, or placebo. MAIN OUTCOMES AND MEASURES: Primary outcomes were measures of safety and tolerability as well as antibody titers. RESULTS: Among 16 enrolled participants, the mean (SD) age was 32.6 (4.4) years; 9 participants were women, and 7 were men. All participants were White, and 1 participant had Hispanic or Latino ethnicity. Treatment adherence was 100%. There were no cases of meningoencephalitis, death, or other serious adverse events (AEs) and no withdrawals as a result of AEs. Most treatment-emergent AEs were of mild intensity (110 of 132 events [83.3%]) and unrelated or unlikely to be related to the ACI-24 vaccine (113 of 132 events [85.6%]). No amyloid-related imaging abnormalities with edema or cerebral microhemorrhage and no evidence of central nervous system inflammation were observed on magnetic resonance imaging scans. Increases in anti-Aβ immunoglobulin G titers were observed in 4 of 12 participants (33.3%) receiving ACI-24 (2 receiving 300 μg and 2 receiving 1000 μg) compared with 0 participants receiving placebo. In addition, a greater increase was observed in plasma Aβ1-40 and Aβ1-42 levels among individuals receiving ACI-24. CONCLUSIONS AND RELEVANCE: In this study, the ACI-24 vaccine was safe and well tolerated in adults with DS. Evidence of immunogenicity along with pharmacodynamic and target engagement were observed, and anti-Aβ antibody titers were not associated with any adverse findings. These results support progression to clinical trials using an optimized formulation of the ACI-24 vaccine among individuals with DS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02738450

Triple exposure: Reducing negative impacts of climate change, blue growth, and conservation on coastal communities

Coastal communities are on the frontlines of three accelerating global change drivers, climate change, blue growth, and the expansion of area-based conservation, leading to a “triple exposure” scenario. Despite efforts to maximize social benefits from climate, development, and conservation, externally driven processes can converge to amplify vulnerabilities and inequalities. Pre-existing social injustices increase the sensitivity of affected individuals to change and limit their capacity to adapt or benefit from the interacting impacts of triple exposure. We argue that external implementors cannot effectively and equitably achieve climate, economic, and conservation goals without prioritizing social justice and building general resilience. We therefore recommend that implementors: (1) address root causes of vulnerability, namely pre-existing social injustices; (2) use participatory systems approaches to improve understanding of local contexts and potential consequences of proposed initiatives; and (3) leverage inclusive partnerships to facilitate collaborative design and implementation. These strategies—applied together and adapted to local contexts—can support well-being, justice, and resilience within coastal communities experiencing rapid change